In-vivo dosimetric analysis in total skin electron beam therapy

BACKGROUND AND PURPOSE: Thermoluminescent dosimetry (TLD) is an important element of total skin electron beam therapy (TSEBT). In this study, we compare radiation dose distributions to provide data for dose variation across anatomic sites. MATERIAL AND METHODS: Retrospectively collected data on 85 p...

Verfasser: Elsayad, Khaled
Moustakis, Christos
Simonsen, Manuela
Bäcker, Dagmar
Haverkamp, Uwe
Eich, Hans-Theodor
Dokumenttypen:Artikel
Medientypen:Text
Erscheinungsdatum:2018
Publikation in MIAMI:15.01.2020
Datum der letzten Änderung:15.01.2020
Angaben zur Ausgabe:[Electronic ed.]
Quelle:Physics and Imaging in Radiation Oncology 6 (2018), 61–65
Schlagwörter:Dosimeter; Cutaneous lymphoma; Leukemia cutis; Mycosis fungoides; Dose distribution; Total skin electron beam
Fachgebiet (DDC):610: Medizin und Gesundheit
Lizenz:CC BY-NC-ND 4.0
Sprache:English
Förderung:Finanziert durch den Open-Access-Publikationsfonds der Westfälischen Wilhelms-Universität Münster (WWU Münster).
Format:PDF-Dokument
URN:urn:nbn:de:hbz:6-32159441911
Weitere Identifikatoren:DOI: 10.1016/j.phro.2018.05.002
Permalink:https://nbn-resolving.de/urn:nbn:de:hbz:6-32159441911
Verwandte Dokumente:
Onlinezugriff:artikel_elsayad_2018.pdf

BACKGROUND AND PURPOSE: Thermoluminescent dosimetry (TLD) is an important element of total skin electron beam therapy (TSEBT). In this study, we compare radiation dose distributions to provide data for dose variation across anatomic sites. MATERIAL AND METHODS: Retrospectively collected data on 85 patients with cutaneous lymphoma or leukemia underwent TSEBT were reviewed. Patients were irradiated on two linear accelerators, in one of two positions (standing, n=77; reclined, n=8) and 1830 in vivo TLD measurements were obtained for various locations on 76 patients. RESULTS: The TLD results showed that the two TSEBT techniques were dosimetrically heterogeneous. At several sites, the dose administered correlated with height, weight, and gender. After the first TLD measurement, fourteen patients (18%) required MU modification, with a mean 10% reduction (range,−25 to +35). Individual TLD results allowed us to customize the boost treatment for each patient. For patients who were evaluated in the standing position, the most common underdosed sites were the axilla, perineum/perianal folds, and soles (each receiving 69%, 20%, and 34% of the prescribed dose, respectively). For patients evaluated in a reclining position, surface dose distribution was more heterogeneous. The sites underdosed most commonly were the axilla and perineum/perianal folds (receiving less than one third of prescribed dose). Significant variables were detected with model building. CONCLUSION: TLD measurements were integral to quality assurance for TSEBT. Dose distribution at several anatomical sites correlated significantly with gender, height, and weight of the treated individual and might be predicted.